Travere Therapeutics, Inc. TVTX Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $78.36M+26.6% | $93.04M+58.9% | $110.93M+205% | $75.15M+133% | $61.9M+43.1% | ||
| —— | —— | —— | —— | —— | ||
| $87.3M+154% | $80.13M+196% | $82.98M+230% | $38.72M+58.3% | $34.38M+51.3% | ||
| $30.7M-9.9% | $30.28M-15.1% | $32M-12.4% | $33.59M-9.2% | $34.07M-9.8% | ||
| $392.68M+4.9% | $437.57M+5.0% | $371.11M+14.3% | $379.57M+2.9% | $374.17M-22.2% | ||
| $3.63M-25.3% | $4.02M-24.6% | $4.32M-29.9% | $4.56M-30.7% | $4.85M-30.1% | ||
| $110.04M+6.0% | $113.87M+9.5% | $109.44M+5.0% | $105.61M+0.4% | $103.82M+2.6% | ||
| $555.19M+1.2% | $605.19M+1.9% | $538.58M+6.8% | $555.31M+0.8% | $548.8M-17.3% | ||
| $12.91M-16.0% | $24.8M+5.4% | $18.23M-21.4% | $19.13M-26.0% | $15.37M-8.1% | ||
| $125.44M-31.3% | $159.9M-20.3% | $135.07M-28.9% | $189.54M+56.3% | $182.46M+5.3% | ||
| $456.46M-11.5% | $490.36M-8.4% | $465.02M-13.1% | $522.56M-2.5% | $515.98M-12.5% | ||
| $9K0.0% | $9K0.0% | $9K+12.5% | $9K+12.5% | $9K+12.5% | ||
| -$1.51B-1.4% | -$1.47B-1.8% | -$1.48B-6.4% | -$1.5B-12.7% | -$1.49B-18.0% | ||
| $98.73M+201% | $114.83M+94.4% | $73.56M+342% | $32.75M+116% | $32.82M-55.7% | ||
| $555.19M+1.2% | $605.19M+1.9% | $538.58M+6.8% | $555.31M+0.8% | $548.8M-17.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Travere Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 3.13 — current assets exceed current liabilities.
- Where does Travere Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Travere Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.